Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 TCR-T cells for NY-ESO-1 Expressing Malignancies
NCT02457650Phase 1Unknown
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Apr 2015
- Primary completion
- Dec 2019
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-NY-ESO-1 TCR-T in bladder carcinoma, breast cancer, esophageal carcinoma and 7 more, sponsored by Shenzhen Second People's Hospital. Primary endpoint: Number of participants with Adverse Events at 8 weeks. Status: unknown.
02
Drugs
anti-NY-ESO-1 TCR-T
03
Conditions
bladder carcinomabreast canceresophageal carcinomalung cancermelanoma
Beyond the preview
Go deeper on NCT02457650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02457650.